Peptides

Details Peptides Peptides

2011-01-04

2011-01-04

Borin, Michael (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C530S324000, C530S326000

Reexamination Certificate

active

07863244

ABSTRACT:
Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.

REFERENCES:
patent: 5856171 (1999-01-01), Korsmeyer
patent: WO 92/14756 (1992-09-01), None
patent: WO 95/32731 (1995-12-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 96/31605 (1996-10-01), None
patent: WO 97/12992 (1997-04-01), None
patent: WO 97/29195 (1997-08-01), None
patent: WO 98/15285 (1998-04-01), None
patent: WO 99/10382 (1999-03-01), None
patent: WO 99/58564 (1999-11-01), None
Rampino et al. (1997), Science 275:967-969, “Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Pheotype”.
Yamamoto et al. (Mar. 1998), Cancer Research 58:997-1003, “Somatic Frameshift Mutations in DNA Mismatch Repair and Proapoptosis Genes in Hereditary Nonpolyposis Colorectal Cancer”.
Markowitz et al. (1995), Science 268:1336-1338, “Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability”.
Gaudernack (1996), Immunotechnology 2:3-9, “T cell responses against mutantras: a basis for novel cancer vaccines”.
Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, “Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study”.
Gjertsen et al. (1996), British Journal of Cancer 74:1828-1833, “Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination”.
Gjertsen et al. (1997), Int. J. Cancer 72:784-790, “Cytotoxic CD4+and CD8+T-Lymphocytes, Generated by Mutant p21-ras(12Val) Peptide Vaccination of a Patient, Recognize . . . Tumour Cells Carrying This Mutation”.
Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, “Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer”.
Barinaga, (1992) Science, vol. 257, pp. 880-881, “Getting Some Backbone: How MHC Binds Peptides”.
Deres et al., (1989) Nature, vol. 342, pp. 561-564, “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine”.
Tighe et al., (1998) Immun. Today, vol. 19(2), pp. 89-97, “Gene vaccination: plasmid DNA is more than just a blueprint”.
Coulie, Pierre G. et al., “A Mutated Intron Sequence Codes for an Antigenic Peptide recognized by Cytolytic T Lymphocytes on a Human Melanoma”, Proc. Natl. Acad. Sci. USA, Immunology, vol. 92, pp. 7976-7980, (Aug. 1995).
Jager, Elke et al., “Immunoselection in vivo: Independent Loss of MHC class I and Melanocyte Differentiation Antigen Expression in Metastatic Melanoma”, Int. J. Cancer, vol. 71, pp. 142-147, (1997).
Saeterdal, Ingvil, et al., “Frameshift-mutation-derived Peptides as Tumor-Specific Antigens in Inherited and Spontaneous Colorectal Cancer”, PNAS, vol. 98, No. 23, pp. 13255-13260, (Nov. 6, 2001).
Samowitz, WS et al., “Transforming Growth Factor-beta Receptor type 2 Mutations and Microsatellite Instability in Sporadic Colorectal Adenomas and Carcinomas”, American Journal of Pathology, vol. 151, pp. 33-35, (1997) (Abstract only).
Vincent et al., “Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β,” Oncogene 15:117-22 (1997).
Brimwell, M, et al., “BAX Frameshift Mutations in Cell Lines Derived From Human Haemopoietic malignancies are Associated with Resistance to Apoptosis and Microsatellite Instability”, Oncogene 16, pp. 1803-1812 (1998).
Moscatello, DK, et al., “A Naturally Occurring Mutuant Human Epidermal Growth Factor Receptor as a Target for Peptide Vaccine Immunotherapy of Tumors”, Cancer Res, pp. 1419-1424 (1997) (abstract only).
Tamura, T et al. “DNA Damage-induced Apoptosis and Ice Gene Induction in Mitogenically Activated T Lymphocytes Require IRF-1”, Leukemia 11, Suppl 3, pp. 439-440 (Apr. 1997) (abstract only).
Yamamoto, H, et al., “Frameshift Somatic Mutations in Gastrointestinal Cancer of the Microsatellite Mutator Phenotype”, Cancer Research 57, pp. 4420-4426 (Oct. 1, 1997).
Malkhosyan, S, et al., “Frameshift Mutator Mutations”, Nature, vol. 382, pp. 499-500 (Aug. 8, 1996).
Korinek, V, et al., “Constitutive Transcriptional Activation by a b-Catenin-Tcf Complex in APC -/- Colon Carcinoma”, Science, New Series, vol. 275, No. 5307, pp. 1784-1787 (Mar. 21, 1997).
Boon, T, et al. “Tumor Antigens Recognized by T Lymphocytes”, Annu. Rev. Immunol., vol. 12, pp. 337-365 (1994).
Abernathy, CR, et al., “Two NF1 mutations: Frameshift in the GAP-related Domain, and Loss of Two Codons Toward the 3′ End of the Gene”, Hum Mutuat, vol. 3, pp. 347-352 (1994) (abstract only).
Sheng, Q, et al., “The DnaJ Domain of Polyomavirus Large T Antigen is Required To Regulate Rb Family Tumor Suppressor Function”, J Virology, pp. 9410-9416 (Dec. 1997) (abstract only).
Lee JH, et al., “Suppression of Metastasis in Human Breast Carcinoma MDA-MB-435 Cells After Transfection with the Metastasis Suppressor Gene, KiSS-1”, Cancer Res, vol. 57, No. 12, pp. 2384-2387 (Jun. 15, 1997) (abstract only).
Thai TH, et al., “Mutations in the BRCA 1 -associated Ring Domain (BARD1) Gene in Primary Breast, Ovarian and Uterine Cancers”, Hum Mol Genet, vol. 7, No. 2, pp. 195-202 (1998) (abstract only).
Hahn, SA, et al., “Mutations of the DPC4/Smad4 Gene in Biliary Tract Carcinoma”, Cancer Res, vol. 58, No. 6, pp. 1124-1126 (Mar. 15, 1998) (abstract only).
Winter SF., et al., “Development of Antibodies Against p53 in Lung Cancer Patients Appears to be Dependent on the Type of p53 Mutation”, Cancer Research, vol. 52, pp. 4168-4174 (Aug. 1, 1992).
Townsend et al. “Source of unique tumour antigens” (1994) Nature 371:662 [XP001189726].
Durrant and Spendlove “Cancer Vaccines” (1996) Q.J. Med. 89:645-51 [XP008107434].

Affiliated with

Also associated with

Rating

Peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2714586